Press Releases Year None20232022202120202019 April 5, 2022 Athira Files Definitive Proxy Statement and Mails Letter to Shareholders April 4, 2022 Athira Pharma Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions March 30, 2022 Athira Pharma Highlights Strong Execution of Strategy and Positioning for the Future March 24, 2022 Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update March 21, 2022 Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors March 21, 2022 Athira Pharma to Participate in Two Upcoming Investor Conferences March 20, 2022 Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress March 17, 2022 Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022 March 14, 2022 Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer’s Disease at AD/PD™ 2022 Congress March 2, 2022 Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 31 - 40 of 93
Year None20232022202120202019 April 5, 2022 Athira Files Definitive Proxy Statement and Mails Letter to Shareholders April 4, 2022 Athira Pharma Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions March 30, 2022 Athira Pharma Highlights Strong Execution of Strategy and Positioning for the Future March 24, 2022 Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update March 21, 2022 Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors March 21, 2022 Athira Pharma to Participate in Two Upcoming Investor Conferences March 20, 2022 Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress March 17, 2022 Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022 March 14, 2022 Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer’s Disease at AD/PD™ 2022 Congress March 2, 2022 Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 31 - 40 of 93